Teacher Retirement System of Texas Decreases Position in United Therapeutics Corporation $UTHR

Key Points

• Teacher Retirement System of Texas reduced its stake in United Therapeutics by 38.9% in Q4, selling 4,305 shares and leaving it with 6,748 shares valued at about $3.29 million.
• Company insiders have been active sellers recently: a director sold 2,910 shares and the CFO sold 9,636 shares, and insiders have offloaded 430,205 shares worth $231.6 million over the past 90 days (insiders now own 10.3%).
• United Therapeutics beat EPS expectations with $7.70 per share and 7.4% YoY revenue growth, and analysts hold a consensus "Moderate Buy" with a target price of $601.50.

Teacher Retirement System of Texas decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 38.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,748 shares of the biotechnology company's stock after selling 4,305 shares during the quarter. Teacher Retirement System of Texas' holdings in United Therapeutics were worth $3,288,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB raised its stake in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after buying an additional 49 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in United Therapeutics in the fourth quarter worth about $48,000. Abich Financial Wealth Management LLC purchased a new stake in shares of United Therapeutics during the third quarter worth about $44,000. WealthCollab LLC increased its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Finally, Rakuten Securities Inc. increased its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 0.0%

Shares of NASDAQ UTHR opened at $566.99 on Tuesday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $607.89. The business's 50 day moving average price is $538.38 and its 200 day moving average price is $495.47. The firm has a market cap of $24.85 billion, a P/E ratio of 20.32, a P/E/G ratio of 1.61 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the firm posted $6.19 EPS. United Therapeutics's revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, research analysts expect that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently commented on UTHR. Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a research note on Monday, December 29th. TD Cowen upped their price target on shares of United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research note on Monday, March 30th. Bank of America raised their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a report on Tuesday, March 31st. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 31st. Finally, UBS Group boosted their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $601.50.

Insider Buying and Selling at United Therapeutics

In related news, Director Christopher Patusky sold 2,910 shares of the firm's stock in a transaction on Friday, April 24th. The shares were sold at an average price of $569.00, for a total transaction of $1,655,790.00. Following the completion of the transaction, the director owned 1,490 shares of the company's stock, valued at $847,810. This trade represents a 66.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO James Edgemond sold 9,636 shares of the company's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $572.21, for a total transaction of $5,513,815.56. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,801,035.96. The trade was a 33.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 430,205 shares of company stock worth $231,615,836 over the last ninety days. 10.30% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.